Stedman's Plus Version 2012 Medical/Pharmaceutical Spellchecker, Starter Kit: Practice Exams, Case Studies and Test Prep
Released: Feb 15, 2012
Publisher: Lippincott, Williams, & Wilkins
Format: CD-ROM, 0 pages
Related ISBN: 9781451146707
Description:
Stedman's Plus Version 2012 Medical/Pharmaceutical Spellchecker contains nearly 500,000 medical, pharmaceutical, and bioscience terms to ensure users the most current, comprehensive, and reliable content on the market. Compatible with a broad range of word processing systems, the Spellchecker is convenient for every user who creates or edits medical documentation. The standard single-user version is available as a Windows® and Macintosh compatible CD-ROM or as a downloadable file via the Stedmans.com or LWW.com websites. The 2012 version includes new medical and equipment terms introduced in 2011 and updated drug terminology drawn from Facts & Comparisons' American Drug Index 2012.
Best prices to buy, sell, or rent ISBN 9781451146752
Frequently Asked Questions about Stedman's Plus Version 2012 Medical/Pharmaceutical Spellchecker, Starter Kit: Practice Exams, Case Studies and Test Prep
You can buy the Stedman's Plus Version 2012 Medical/Pharmaceutical Spellchecker, Starter Kit: Practice Exams, Case Studies and Test Prep book at one of 20+ online bookstores with BookScouter, the website that helps find the best deal across the web. Currently, the best offer comes from and is $ for the .
If you’re interested in selling back the Stedman's Plus Version 2012 Medical/Pharmaceutical Spellchecker, Starter Kit: Practice Exams, Case Studies and Test Prep book, you can always look up BookScouter for the best deal. BookScouter checks 30+ buyback vendors with a single search and gives you actual information on buyback pricing instantly.
As for the Stedman's Plus Version 2012 Medical/Pharmaceutical Spellchecker, Starter Kit: Practice Exams, Case Studies and Test Prep book, the best buyback offer comes from and is $ for the book in good condition.
Not enough insights yet.
Not enough insights yet.